These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8236454)

  • 1. Inhibitors of Ras farnesyltransferases.
    Tamanoi F
    Trends Biochem Sci; 1993 Sep; 18(9):349-53. PubMed ID: 8236454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics.
    Koblan KS; Kohl NE; Omer CA; Anthony NJ; Conner MW; deSolms SJ; Williams TM; Graham SL; Hartman GD; Oliff A; Gibbs JB
    Biochem Soc Trans; 1996 Aug; 24(3):688-92. PubMed ID: 8878827
    [No Abstract]   [Full Text] [Related]  

  • 3. Farnesylation of p21 Ras proteins in Xenopus oocytes.
    Zhao J; Kung HF; Manne V
    Cell Mol Biol Res; 1994; 40(4):313-21. PubMed ID: 7866432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?
    Cox AD; Der CJ
    Biochim Biophys Acta; 1997 Aug; 1333(1):F51-71. PubMed ID: 9294018
    [No Abstract]   [Full Text] [Related]  

  • 5. [Anti tumor activity of farnesyl transferase inhibitor].
    Yoshimatsu K; Nagasu T
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of farnesyltransferase and Ras processing peptidase.
    Hall CC; Watkins JD; Ferguson SB; Foley LH; Georgopapadakou NH
    Biochem Biophys Res Commun; 1995 Dec; 217(3):728-32. PubMed ID: 8554591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.
    Kohl NE; Mosser SD; deSolms SJ; Giuliani EA; Pompliano DL; Graham SL; Smith RL; Scolnick EM; Oliff A; Gibbs JB
    Science; 1993 Jun; 260(5116):1934-7. PubMed ID: 8316833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyltransferase inhibitors and anti-Ras therapy.
    Gibbs JB; Kohl NE; Koblan KS; Omer CA; Sepp-Lorenzino L; Rosen N; Anthony NJ; Conner MW; deSolms SJ; Williams TM; Graham SL; Hartman GD; Oliff A
    Breast Cancer Res Treat; 1996; 38(1):75-83. PubMed ID: 8825125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
    Williams TM; Ciccarone TM; MacTough SC; Bock RL; Conner MW; Davide JP; Hamilton K; Koblan KS; Kohl NE; Kral AM; Mosser SD; Omer CA; Pompliano DL; Rands E; Schaber MD; Shah D; Wilson FR; Gibbs JB; Graham SL; Hartman GD; Oliff AI; Smith RL
    J Med Chem; 1996 Mar; 39(7):1345-8. PubMed ID: 8691462
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase.
    Burns CJ; Guitton JD; Baudoin B; Lelièvre Y; Duchesne M; Parker F; Fromage N; Commerçon A
    J Med Chem; 1997 Jun; 40(12):1763-7. PubMed ID: 9191950
    [No Abstract]   [Full Text] [Related]  

  • 11. Farnesyltransferase as a target for anticancer drug design.
    Qian Y; Sebti SM; Hamilton AD
    Biopolymers; 1997; 43(1):25-41. PubMed ID: 9174410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
    Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
    Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p21ras CA1A2X peptidomimetics.
    Nigam M; Seong CM; Qian Y; Hamilton AD; Sebti SM
    J Biol Chem; 1993 Oct; 268(28):20695-8. PubMed ID: 8407887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.
    Gibbs JB; Oliff A
    Annu Rev Pharmacol Toxicol; 1997; 37():143-66. PubMed ID: 9131250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of yeast for identification of farnesyltransferase inhibitors and for generation of mutant farnesyltransferases.
    Tamanoi F; Mitsuzawa H
    Methods Enzymol; 1995; 255():82-91. PubMed ID: 8524140
    [No Abstract]   [Full Text] [Related]  

  • 16. [Inhibitors of isoprenylation of ras p21].
    Yoshimatsu K
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
    Nammi S; Lodagala DS
    Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel anticancer agents move closer to reality.
    Travis J
    Science; 1993 Jun; 260(5116):1877-8. PubMed ID: 8316828
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthesis and conformational analysis of peptide inhibitors of farnesyltransferase.
    Byk G; Lelievre Y; Duchesne M; Clerc FF; Scherman D; Guitton JD
    Bioorg Med Chem; 1997 Jan; 5(1):115-24. PubMed ID: 9043663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
    Lerner EC; Hamilton AD; Sebti SM
    Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.